Skip to Content

Staphcillin (methicillin) Disease Interactions

There are 5 disease interactions with Staphcillin (methicillin):

Major

Antibiotics (applies to Staphcillin) colitis

Major Potential Hazard, Moderate plausibility. Applicable conditions: Colitis/Enteritis (Noninfectious)

Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis. The most common culprits include clindamycin and lincomycin. Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development. Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea after antibacterial use. Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary. Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity. Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.

References

  1. Moriarty HJ, Scobie BA "Pseudomembranous colitis in a patient on rifampicin and ethambutol." N Z Med J 04/23/80 (1980): 294-5
  2. Thomas E, Mehta JB "Pseudomembranous colitis due to oxacillin therapy." South Med J 77 (1984): 532-3
  3. Bauwens JE, McFarland LV, Melcher SA "Recurrent clostridium difficile disease following ciprofloxacin use." Ann Pharmacother 31 (1997): 1090
  4. Davies J, Beck E "Recurrent colitis following antibiotic-associated pseudomembranous colitis." Postgrad Med J 57 (1981): 599-601
  5. Dan M, Samra Z "Clostridium difficile colitis associated with ofloxacin therapy." Am J Med 87 (1989): 479
  6. Harmon T, Burkhart G, Applebaum H "Perforated pseudomembranous colitis in the breast-fed infant." J Pediatr Surg 27 (1992): 744-6
  7. Milstone EB, McDonald AJ, Scholhamer CF Jr "Pseudomembranous colitis after topical application of clindamycin." Arch Dermatol 117 (1981): 154-5
  8. Cone JB, Wetzel W "Toxic megacolon secondary to pseudomembranous colitis." Dis Colon Rectum 25 (1982): 478-82
  9. Burt RA "A review of the drug events reported by 12,917 patients treated with cephalexin." Postgrad Med J 59 (1983): 47-50,51-3
  10. Cannon SR, Dyson PH, Sanderson PJ "Pseudomembranous colitis associated with antibiotic prophylaxis in orthopaedic surgery." J Bone Joint Surg Br 70-B (1988): 600-2
  11. Miller DL, Sedlack JD, Holt RW "Perforation complicating rifampin-associated pseudomembranous enteritis." Arch Surg 124 (1989): 1082
  12. Wang C, Calandra GB, Aziz MA, Brown KR "Efficacy and safety of imipenem/cilastatin: a review of worldwide clinical experience." Rev Infect Dis 7 (1985): s528-36
  13. Miller SN, Ringler RP "Vancomycin-induced pseudomembranous colitis." J Clin Gastroenterol 9 (1987): 114-5
  14. Bernstein L "Adverse reaction to trimethoprim-sulfamethoxazole, with particular reference to long-term therapy." Can Med Assoc J 112 (1975): s96-8
  15. Calandra GB, Brown KR, Grad LC, et al "Review of adverse experiences and tolerability in the first 2,516 patients treated with imipenem/cilastatin." Am J Med 78 (1985): 73-8
  16. Pokorney BH, Nichols TW, Jr "Pseudomembranous colitis. A complication of sulfasalazine therapy in a patient with Crohn's colitis." Am J Gastroenterol 76 (1981): 374-6
  17. Sankarankutty M, McGeorge D, Galasko CS "Pseudomembranous colitis following cephradine prophylaxis." Postgrad Med J 58 (1982): 726-8
  18. Van Ness MM, Cattau EL Jr "Fulminant colitis complicating antibiotic-associated pseudomembranous colitis: case report and review of the clinical manifestations and treatment." Am J Gastroenterol 82 (1987): 374-7
  19. Hutcheon DF, Milligan FD, Yardley JH, Hendrix TR "Cephalosporin-associated pseudomembranous colitis." Am J Dig Dis 23 (1978): 321-6
  20. Gordin F, Gibert C, Schmidt ME "Clostridium difficile colitis associated with trimethoprim-sulfamethoxazole given as prophylaxis for pneumocystis carinii pneumonia." Am J Med 96 (1994): 94-5
  21. Bingley PJ, Harding GM "Clostridium difficile colitis following treatment with metronidazole and vancomycin." Postgrad Med J 63 (1987): 993-4
  22. Hinton NA "The effect of oral tetracycline HCl and doxycycline on the intestinal flora." Curr Ther Res Clin Exp 12 (1970): 341-52
  23. Ring FA, Hershfield NB, Machin GA, Scott RB "Sulfasalazine-induced colitis complicating idiopathic ulcerative colitis." Can Med Assoc J 131 (1984): 43-5
  24. Saginur R, Hawley CR, Bartlett JG "Colitis associated with metronidazole therapy." J Infect Dis 141 (1980): 772-4
  25. Friedman RJ, Mayer IE, Galambos JT, Hersh T "Oxacillin-induced pseudomembranous colitis." Am J Gastroenterol 73 (1980): 445-7
  26. "Multum Information Services, Inc. Expert Review Panel"
  27. Midtvedt T, Carlstedt-Duke B, Hoverstad T, et al "Influence of peroral antibiotics upon the biotransformatory activity of the intestinal microflora in healthy subjects." Eur J Clin Invest 16 (1986): 11-7
  28. Leigh DA, Simmons K, Williams S "Gastrointestinal side effects following clindamycin and lincomycin treatment: a follow up study." J Antimicrob Chemother 6 (1980): 639-45
  29. Altamirano A, Bondani A "Adverse reactions to furazolidone and other drugs. A comparative review." Scand J Gastroenterol Suppl 169 (1989): 70-80
  30. Hecht JR, Olinger EJ "Clostridium difficile colitis secondary to intravenous vancomycin." Dig Dis Sci 34 (1989): 148-9
  31. Brause BD, Romankiewicz JA, Gotz V, Franklin JE Jr, Roberts RB "Comparative study of diarrhea associated with clindamycin and ampicillin therapy." Am J Gastroenterol 73 (1980): 244-8
  32. Boriello SP, Jones RH, Phillips I "Rifampicin-associated pseudomembranous colitis." Br Med J 281 (1980): 1180-1
  33. Klinger D, Radford P, Collin J "Pneumoperitoneum without faecal peritonitis in a patient with pseudomembranous colitis." Br Med J 288 (1984): 1271-2
  34. Saadah HA "Carbenicillin and pseudomembranous enterocolitis." Ann Intern Med 93 (1980): 645
  35. Lyon JA "Imipenem/cilastatin: the first carbapenem antibiotic." Drug Intell Clin Pharm 19 (1985): 894-8
  36. Daly JJ, Chowdary KV "Pseudomembranous colitis secondary to metronidazole." Dig Dis Sci 28 (1983): 573-4
  37. Trexler MF, Fraser TG, Jones MP "Fulminant pseudomembranous colitis caused by clindamycin phosphate vaginal cream." Am J Gastroenterol 92 (1997): 2112-3
  38. Edlund C, Brismar B, Nord CE "Effect of lomefloxacin on the normal oral and intestinal microflora." Eur J Clin Microbiol Infect Dis 1 (1990): 35-9
  39. O'Meara TF, Simmons RA "Carbenicillin and pseudomembranous enterocolitis." Ann Intern Med 92 (1980): 440-1
  40. Meadowcroft AM, Diaz PR, Latham GS "Clostridium difficile toxin-induced colitis after use of clindmycin phosphate vaginal cream." Ann Pharmacother 32 (1998): 309-11
  41. Ehrenpreis ED, Lievens MW, Craig RM "Clostridium difficile-associated diarrhea after norfloxacin." J Clin Gastroenterol 12 (1990): 188-9
  42. Osler T, Lott D, Bordley J, et al "Cefazolin-induced pseudomembranous colitis resulting in perforation of the sigmoid colon." Dis Colon Rectum 29 (1986): 140-3
  43. Parry MF, Rha CK "Pseudomembranous colitis caused by topical clindamycin phosphate." Arch Dermatol 122 (1986): 583-4
  44. Clissold SP, Todd PA, Campoli-Richards DM "Imipenem/cilastatin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy." Drugs 33 (1987): 185-241
  45. Sugarman B "Trimethoprim-sulfamethoxazole, pseudomembranous colitis, and spinal cord injury." South Med J 78 (1985): 711-3
  46. Golledge CL, Riley TV "Clostridium difficile-associated diarrhoea after doxycycline malaria prophylaxis." Lancet 345 (1995): 1377-8
  47. Edlund C, Lidbeck A, Kager L, Nord CE "Effect of enoxacin on colonic microflora of healthy volunteers." Eur J Clin Microbiol 6 (1987): 298-300
View all 47 references
Major

Penicillinase-resistant PCNs (applies to Staphcillin) marrow toxicity

Major Potential Hazard, Moderate plausibility. Applicable conditions: Neutropenia, Thrombocytopenia

The use of penicillinase-resistant penicillins has been associated with adverse hematologic effects, including neutropenia, leukopenia, granulocytopenia and thrombocytopenia, particularly when given in high parenteral dosages. Agranulocytosis and prolonged bleeding time have been reported rarely. Therapy with penicillinase-resistant penicillins should be administered cautiously in patients with preexisting blood dyscrasias or bone marrow depression, and hematopoietic function should be monitored. Blood counts with differential should be performed prior to initiation of therapy and 1 to 3 times weekly during therapy. Hematologic abnormalities are generally reversible and resolve within several days to two weeks following discontinuation of therapy.

References

  1. "Product Information. Staphcillin (methicillin)." Apothecon Inc, Plainsboro, NJ.
  2. "Product Information. Dynapen (dicloxacillin)." Apothecon Inc, Plainsboro, NJ.
  3. Leventhal JM, Silken AB "Oxacillin-induced neutropenia in children." J Pediatr 89 (1976): 769-71
  4. Carpenter J "Neutropenia induced by semisynthetic penicillin." South Med J 73 (1980): 745-8
  5. Brook I "Leukopenia and granulocytopenia after oxacillin therapy." South Med J 70 (1977): 565-6
  6. Clotet B, Vea AM, Rubies-Prat J, Sala MF "Cloxacillin-induced leukopenia." Arch Intern Med 145 (1985): 1531
  7. Slovick FT, Bamberger DM, Stark KR "Spontaneous clostridial myonecrosis in a man with drug-induced agranulocytosis." South Med J 82 (1989): 1272-4
  8. Westerman EL, Bradshaw MW, Williams TW "Agranulocytosis during therapy with orally administered cloxacillin." Am J Clin Pathol 69 (1978): 559-60
  9. Kitzing W, Nelson JD, Mohs E "Comparative toxicities of methicillin and nafcillin." Am J Dis Child 135 (1981): 52-5
  10. Olaison L, Alestig K "A prospective study of neutropenia induced by high doses of B-lactam antiobiotics." J Antimicrob Chemother 25 (1990): 449-53
  11. Ahern MJ, Hicks JE, Andriole VT "Neutropenia during high dose intravenous oxacillin therapy." Yale J Biol Med 49 (1976): 351-60
  12. Alexander DP, Russo ME, Fohrman DE, Rothstein G "Nafcillin-induced platelet dysfunction and bleeding." Antimicrob Agents Chemother 23 (1983): 59-62
  13. "Product Information. Unipen (nafcillin)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  14. Carpenter J "Neutropenia induced by semisynthetic penicillin." South Med J 73 (1980): 745-8
  15. Jeter EK, Scott A, Kizer J, Lazarchick J "Impaired platelet function associated with parenteral nafcillin." Ann Clin Lab Sci 20 (1990): 79-84
  16. Fallon JA, Tall AR, Janis MG, Brauer MJ "Oxacillin-induced granulocytopenia." Acta Haematol 59 (1978): 163-70
  17. Passoff TL, Sherry HS "Oxacillin induced neutropenia. A case report." Clin Orthop 135 (1978): 69-70
  18. Walbroehl GS, John PG "Antibiotic-associated neutropenia." Am Fam Physician 45 (1992): 2237-41
  19. Alexander DP, Russo ME, Fohrman DE, Rothstein G "Nafcillin-induced platelet dysfunction and bleeding." Antimicrob Agents Chemother 23 (1983): 59-62
  20. Klein JO, Finland M "The new penicillins (concluded)." N Engl J Med 269 (1963): 1129-34
  21. Chu JY, O'Connor DM, Schmidt RR "The mechanism of oxacillin-induced neutropenia." J Pediatr 90 (1977): 668-9
  22. Kahn JB "Oxacillin-induced agranulocytosis." JAMA 240 (1978): 2632
  23. Godin M, Deshayes P, Ducastelle T, Delpech A, Leloet X, Fillastre JP "Agranulocytosis, haemorrhagic cystitis and acute interstitial nephritis during methicillin therapy." J Antimicrob Chemother 6 (1980): 296-7
  24. Couchonnal GJ, Hinthorn DR, Hodges GR, Liu C "Nafcillin-associated granulocytopenia." South Med J 71 (1978): 1356-8
  25. "Product Information. Tegopen (cloxacillin)." Apothecon Inc, Plainsboro, NJ.
  26. "Product Information. Bactocill (oxacillin)." SmithKline Beecham, Philadelphia, PA.
  27. Neftel K, Muller MR, Hauser SP, Walti M, de Weck AL "More on penicillin-induced leukopenia." N Engl J Med 308 (1983): 901-2
  28. Greene GR, Cohen E "Nafcillin-induced neutropenia in children." Pediatrics 61 (1978): 94-7
  29. Shah I, Kumar KS, Lerner AM "Agranulocytosis associated with chronic oral administration of cloxacillin for suppression of staphylococcal osteomyelitis." Am J Hematol 12 (1982): 203-6
View all 29 references
Moderate

Beta-lactams (parenteral) (applies to Staphcillin) renal dysfunction

Moderate Potential Hazard, High plausibility.

Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites. The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function. Neurotoxic reactions, including encephalopathy, asterixis, myoclonus, seizures and coma, have been reported in such patients treated parenterally with these agents. Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling. Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.

References

  1. "Product Information. Zinacef (cefuroxime)." Glaxo Wellcome, Research Triangle Park, NC.
  2. Jackson EA, McLeod DC "Pharmacokinetics and dosing of antimicrobial agents in renal impairment, part I." Am J Hosp Pharm 31 (1974): 36-52
  3. Pazin GJ, Schwartz SN, Ho M, Lyon JA, Pasculle AW "Treatment of septicemic patients with cefoxitin: pharmacokinetics in renal insufficiency." Rev Infect Dis 1 (1979): 189-94
  4. Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 Suppl 1 (1985): s145-50
  5. Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR "Nephrotoxicity associated with cephalothin administration." Arch Intern Med 135 (1975): 797-801
  6. Kampf D, Schurig R, Korsukewitz I, Bruckner O "Cefoxitin pharmacokinetics: relation to three different renal clearance studies in patients with variuos degrees of renal insufficiency." Antimicrob Agents Chemother 20 (1981): 741-6
  7. Blum RA, Kohli RK, Harrison NJ, Schentag JJ "Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis." Antimicrob Agents Chemother 33 (1989): 1470-6
  8. Aronoff GR, Sloan RS, Brier ME, Luft FC "The effect of piperacillin dose on elimination kinetics in renal impairment." Eur J Clin Pharmacol 24 (1983): 543-7
  9. Smith BR, LeFrock JL, Thyrum PT, et al "Cefotetan pharmacokinetics in volunteers with various degrees of renal function." Antimicrob Agents Chemother 29 (1986): 887-93
  10. Meyers BR, Hirschman SZ "Pharmacokinetics of cefamandole in patients with renal failure." Antimicrob Agents Chemother 11 (1977): 248-50
  11. Davies M, Morgan JR, Anand C "Administration of ticarcillin to patients with severe renal failure." Chemotherapy 20 (1974): 339-41
  12. McCloskey RV, Terry EE, McCracken AW, Sweeney MJ, Forland MF "Effect of hemodialysis and renal failure on serum and urine concentrations of cephapirin sodium." Antimicrob Agents Chemother 1 (1972): 90-3
  13. Grcevska L, Polenakovic M "Second attack of acute tubulointerstitionephritis induced by cefataxim and pregnancy." Nephron 72 (1996): 354-5
  14. Wade JC, Schimpff SC, Wiernik PH "Antibiotic combination - associated nephrotoxicity in granulocytopenic patients with cancer." Arch Intern Med 141 (1981): 1789-93
  15. Pasternak DP, Stephens BG "Reversible nephrotoxicity associated with cephalothin therapy." Arch Intern Med 135 (1975): 599-602
  16. Fillastre JP, Leroy A, Humbert G, Godin M "Pharmacokinetics of cefotaxime in subjects with normal and impaired renal function." J Antimicrob Chemother 6 (1980): 103-11
  17. Madhavan T, Yaremchuk K, Levin N, et al "Effects of renal failure and dialysis on cefazolin pharmacokinetics." Antimicrob Agents Chemother 8 (1975): 63-6
  18. "Product Information. Mefoxin (cefoxitin)." Merck & Co, Inc, West Point, PA.
  19. Brogard JM, Kopferschmitt J, Spach MO, et al "Cefamandole pharmacokinetics and dosage adjustments in relation to renal function." J Clin Pharmacol 19 (1979): 366-77
  20. Welage LS, Schultz RW, Schentag JJ "Pharmacokinetics of ceftazidime in patients with renal insufficiency." Antimicrob Agents Chemother 25 (1984): 201-4
  21. Sherman RA, Eisinger RP, Weinstein MP, Samel J "Cefoxitin-induced pseudo acute renal failure." Clin Ther 4 (1981): 114-7
  22. Wise R, Wright N, Wills PJ "Pharmacolgy of cefotaxime and its desacetyl metabolite in renal and hepatic disease." Antimicrob Agents Chemother 19 (1981): 526-31
  23. Burton JR, Lichtenstein NS, Colvin RB, Hyslop NE, Jr "Acute renal failure during cephalothin therapy." JAMA 229 (1974): 679-82
  24. Bechtel TP, Slaughter RL, Moore TD "Seizures associated with high cerebrospinal fluid concentrations of cefazolin." Am J Hosp Pharm 37 (1980): 271-3
  25. "Product Information. Staphcillin (methicillin)." Apothecon Inc, Plainsboro, NJ.
  26. Fillastre JP, Leroy A, Godin M, Oksenhendler G, Humbert G "Pharmacokinetics of cefoxitin sodium in normal subjects and in uraemic patients." J Antimicrob Chemother 4 (1978): 79-83
  27. Haskell RJ, Fujita NK, Stevenson JA, Border WA "Cefoxitin-induced interstitial nephritis." Arch Intern Med 141 (1981): 1557
  28. Fillastre JP, Leroy A, Baudoin C, et al "Pharmacokinetics of aztreonam in patients with chronic renal failure." Clin Pharmacokinet 10 (1985): 91-100
  29. Walstad RA, Nilsen OG, Berg KJ "Pharmacokinetics and clinical effects of cefuroxime in patients with severe renal insufficiency." Eur J Clin Pharmacol 24 (1983): 391-8
  30. Lewis JA, Rindone JP "Acute interstitial nephritis associated with cephapirin." Drug Intell Clin Pharm 21 (1987): 380-1
  31. Ohkawa M, Nakashima T, Shoda R, et al "Pharmacokinetics of ceftazidime in patients with renal insufficiency and in those undergoing hemodialysis." Chemotherapy 31 (1985): 410-6
  32. Dubb J, Actor P, Pitkin D, et al "Ceftizoxime kinetics and renal handling." Clin Pharmacol Ther 31 (1982): 516-21
  33. Wright N, Wise R "The elimination of sulbactam alone and combined with ampicillin in patients with renal dysfunction." J Antimicrob Chemother 11 (1983): 583-7
  34. "Product Information. Mandol (cefamandole)." Lilly, Eli and Company, Indianapolis, IN.
  35. Klion AD, Kallsen J, Cowl CT, Nauseef WM "Ceftazidime-related nonconvulsive status epilepticus." Arch Intern Med 154 (1994): 586-9
  36. Yamasaku F, Tsuchida R, Usada Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970): 57-9
  37. Aronoff GR, Wolen RL, Obermeyer BD, Black HR "Pharmacokinetics and protein binding of cefamandole and its 1-methyl-1 H-tetrazole-5-thiol side chain in subjects with normal and impaired renal function." J Infect Dis 153 (1986): 1069-74
  38. Rodjer S, Alestig K, Bergmark J, et al "Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects." J Antimicrob Chemother 20 (1987): 109-16
  39. "Product Information. Fortaz (ceftazidime)." Glaxo Wellcome, Research Triangle Park, NC.
  40. "Product Information. Maxipime (cefepime)." Bristol-Myers Squibb, Princeton, NJ.
  41. Oe PL, Simonian S, Verhoef J "Pharmacokinetics of the new penicillins." Chemotherapy 19 (1973): 279-88
  42. Czerwinski AW, Pederson JA, Barry JP "Cefazolin plasma concentrations and urinary excretion in patients with renal impairment." J Clin Pharmacol 14 (1974): 560-6
  43. Ortiz A, Martin-Llonch N, Garron MP, et al "Cefazolin-induced encephalopathy in uremic patients." Rev Infect Dis 13 (1991): 772-3
  44. Hardin TC, Butler SC, Ross S, Wakeford JH, Jorgensen JH "Comparison of ampicillin-sulbactam and ticarcillin-clavulanic acid in patients with chronic renal failure - effects of differential pharmacokinetics on serum bactericidal activity." Pharmacotherapy 14 (1994): 147-52
  45. Smith H, Lerner PI, Weinstein L "Neurotoxicity and "massive" intravenous therapy with penicillin." Arch Intern Med 120 (1967): 47-53
  46. Benner EJ "Renal damage associated with prolonged administration of ampicillin, cephaloridine, and cephalothin." Antimicrob Agents Chemother 9 (1969): 417-20
  47. Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978): s88-97
  48. Hansen MM, Kaaber K "Nephrotoxicity in combined cephalothin and gentamicin therapy." Acta Med Scand 201 (1977): 463-7
  49. al Shohaib S, Satti MS, Abunijem Z "Acute interstitial nephritis due to cefotaxime." Nephron 73 (1996): 725
  50. Kirby WM, de Maine JB, Serrill WS "Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients." Postgrad Med J 47 Suppl (1971): 41-6
  51. Frimodt-Moller N, Maigaard S, Toothaker RD, et al "Mezlocillin pharmacokinetics after single intravenous doses to patients with various degrees of renal function." Antimicrob Agents Chemother 17 (1980): 599-607
  52. Pitkin D, Dubb J, Actor P, et al "Kinetics and renal handling of cefonicid." Clin Pharmacol Ther 30 (1981): 587-93
  53. "Product Information. Ticar (ticarcillin)." SmithKline Beecham, Philadelphia, PA.
  54. Mellin H-E, Welling PG, Madsen PO "Pharmacokinetics of cefamandole in patients with normal and impaired renal function." Antimicrob Agents Chemother 11 (1977): 262-6
  55. Fillastre J-P, Fourtillan J-B, Leroy A, et al "Pharmacokinetics of cefonicid in uraemic patients." J Antimicrob Chemother 18 (1986): 203-11
  56. Martinez-Rodriguez JE, Barriga FJ, Santamaria J, et al. "Nonconvulsive status epilepticus associated with cephalosporins in patients with renal failure." Am J Med 111 (2001): 115-9
  57. Garcia MJ, Dominguez-Gil A, Tabernero JM, Tomero JA "Pharmacokinetics of cefoxitin in patients with normal or impaired renal function." Eur J Clin Pharmacol 16 (1979): 119-24
  58. "Product Information. Cefadyl (cephapirin)." Apothecon Inc, Plainsboro, NJ.
  59. New PS, Wells CE "Cerebral toxicity associated with massive intravenous penicillin therapy." Neurology 15 (1965): 1053-8
  60. Aronoff GR, Sloan RS, Stanish RA, Fineberg NS "Mezlocillin dose dependent elimination kinetics in renal impairment." Eur J Clin Pharmacol 21 (1982): 505-9
  61. Barriere SL, Gambertoglio JG, Alexander DR, et al "Pharmacokinetic disposition of cefonicid in patients with renal failure and receiving hemodialysis." Rev Infect Dis 6 (1984): s809-15
  62. Blair AD, Maxwell BM, Forland SC, et al "Cefonicid kinetics in subjects with normal and impaired renal function." Clin Pharmacol Ther 35 (1984): 798-803
  63. Craig CP, Rifkin SI "Pharmacokinetics and hemodialyzability of cefazolin in uremic patients." Clin Pharmacol Ther 19 (1976): 825-9
  64. Ings RM, Reeves DS, White LP, et al "The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination." J Pharmacokinet Biopharm 13 (1985): 121-42
  65. Doluisio JT "Clinical pharmacokinetics of cefotaxime in patients with normal and reduced renal function." Rev Infect Dis 4 Suppl (1982): s333-45
  66. Barrons RW, Murray KM, Richey RM "Populations at risk for penicillin-induced seizures." Ann Pharmacother 26 (1992): 26-9
  67. Wu MJ, Narsette TA, Hussey JL, Weinstein AB, Wen SF "Cephalothin neurotoxicity in renal failure." Ann Intern Med 89 (1978): 429
  68. Foord RD "Cephaloridine, cephalothin and the kidney." J Antimicrob Chemother 1 (1975): 119-33
  69. Jusko WJ, Lewis GP, Schmitt GW "Ampicillin and hetacillin pharmacokinetics in normal and anephric subjects." Clin Pharmacol Ther 14 (1972): 90-9
  70. Matzke GR, Abraham PA, Halstenson CE, Keane WF "Cefotaxime and desacetylcefotaxime kinetics in renal impairment." Clin Pharmacol Ther 38 (1985): 31-6
  71. Engle JE, Drago J, Carlin B, Schoolwerth AC "Letter: Reversible acute renal failure after cephalothin." Ann Intern Med 83 (1975): 232-3
  72. Jackson GD, Berkovic SF "Ceftazidime encephalopathy: absence status and toxic hallucinations." J Neurol Neurosurg Psychiatry 55 (1992): 333-4
  73. Ohkawa M, Okasho A, Motoi I, et al "Elimination kinetics of cefotaxime and desacetylcefotaxime in patients with renal insufficiency and during hemodialysis." Chemotherapy 29 (1983): 4-12
  74. Kowalsky SF, Echols RM, Venezia AR, Andrews EA "Pharmacokinetics of ceftizoxime in subjects with various degrees of renal function." Antimicrob Agents Chemother 24 (1983): 151-5
  75. Smyth RD, Pfeffer M, Glick A, et al "Clinical pharmacokinetics and safety of high doses of ceforanide (BL-S786R) and cefazolin." Antimicrob Agents Chemother 16 (1979): 615-21
  76. Bulger RJ, Lindholm DD, Murray JS, Kirby WM "Effects of uremia on methicillin and oxacillin blood levels." JAMA 187 (1964): 319-22
  77. "Product Information. Claforan (cefotaxime)." Hoechst Marion-Roussel Inc, Kansas City, MO.
  78. Yamasaku F, Tsuchida R, Usuda Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970): 57-9
  79. Gibaldi M, Perrier D "Drug distribution and renal failure." J Clin Pharmacol 12 (1972): 201-4
  80. Chow M, Quintiliani R, Cunha BA, et al "Pharmacokinetics of high-dose oral cephalosporins." J Clin Pharmacol 19 (1979): 185-94
  81. Thompson MI, Russo ME, Matsen JM, Atkin-Thor E "Piperacillin pharmacokinetics in subjects with chronic renal failure." Antimicrob Agents Chemother 19 (1981): 450-3
  82. Douglas MA, Quandt CM, Stanley DA "Ceftazidime-induced encephalopathy in a patient with renal impairment." Arch Neurol 45 (1988): 936-7
  83. "Product Information. Pipracil (piperacillin)." Lederle Laboratories, Wayne, NJ.
  84. "Product Information. Tazicef (ceftazidime)." SmithKline Beecham, Philadelphia, PA.
  85. Brogard JM, Pinget M, Brandt C, Lavillaureix J "Pharmacokinetics of cefazolin in patients with renal failure: special reference to hemodialysis." J Clin Pharmacol 17 (1977): 225-30
  86. Czerwinski AW, Pederson JA "Pharmacokinetics of cefamandole in patients with renal impairment." Antimicrob Agents Chemother 15 (1979): 161-4
  87. Simpson IJ "Nephrotoxicity and acute renal failure associated with cephalothin and cephaloridine." N Z Med J 74 (1971): 312-5
  88. "Product Information. Monocid (cefonicid)." SmithKline Beecham, Philadelphia, PA.
  89. Csanyi P, Rado JP, Hormay M "Acute renal failure due to cephamandole." Br Med J 296 (1988): 455
  90. Parry MF, Neu HC "Pharmacokinetics of ticarcillin in patients with abnormal renal function." J Infect Dis 133 (1976): 46-9
  91. Barbhaiya RH, Knupp CA, Forgue ST, Matzke GR, Halstenson CE, Opsahl JA, Pittman KA "Disposition of the cephalosporin cefepime in normal and renally impaired subjects." Drug Metab Dispos 19 (1991): 68-73
  92. Mihindu JC, Scheld WM, Bolton ND, Spyker DA, Swabb EA, Bolton K "Pharmacokinetics of aztreonam in patients with various degrees of renal dysfunction." Antimicrob Agents Chemother 24 (1983): 252-61
  93. "Product Information. Ceftin (cefuroxime)." Glaxo Wellcome, Research Triangle Park, NC.
  94. Ohkawa M, Hirano S, Tokunaga S, et al "Pharmacokinetics of cefotetan in normal subjects and patients with impaired renal function." Antimicrob Agents Chemother 23 (1983): 31-5
  95. Welling PG, Craig WA, Amidon GL, Kunin CM "Pharmacokinetics of cefazolin in normal and uremic subjects." Clin Pharmacol Ther 15 (1973): 344-53
  96. Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978): s88-99
  97. Ackerman BH, Ross J, Tofte RW, Rotschafer JC "Effect of decreased renal function on the pharmacokinetics of ceftazidime." Antimicrob Agents Chemother 25 (1984): 785-6
  98. Barbhaiya RH, Knupp CA, Forgue ST, Matzke GR, Guay DR, Pittman KA "Pharmacokinetics of cefepime in subjects with renal insufficiency." Clin Pharmacol Ther 48 (1990): 268-76
  99. Toll LL, Lee M, Sharifi R "Cefoxitin-induced interstitial nephritis." South Med J 80 (1987): 274-5
  100. Al-Zahawi MF, Sprott MS, Hendrick DJ "Hallucinations in association with ceftazidime." Br Med J 297 (1988): 858
  101. Plaut ME, O'Connell CJ, Pabico RC, Davidson D "Penicillin handling in normal and azotemic patients." J Lab Clin Med 74 (1969): 12-8
  102. Barrientos A, Bello I, Gutierrez-Millet V "Letter; Renal failure and cephalothin." Ann Intern Med 84 (1976): 612
  103. Reitberg DP, Marble DA, Schultz RW, Whall TJ, Schentag JJ "Pharmacokinetics of cefoperazone (2.0 g) and sulbactam (1.0 g) coadministered to subjects with normal renal function, patients with decreased renal function, and patients with end-stage renal disease on hemodialysis." Antimicrob Agents Chemother 32 (1988): 503-9
  104. Ings RM, Fillastre J-P, Godin M, et al "The pharmacokinetics of cefotaxime and its metabolites in subjects with normal and impaired renal function." Rev Infect Dis 4 (1982): s379-91
  105. Bryan CS, Stone WJ ""Comparably massive" penicillin G therapy in renal failure." Ann Intern Med 82 (1975): 189-95
  106. Reddy J, Bailey RR "Cefoxitin-associated renal failure." N Z Med J 93 (1981): 337-9
  107. Trollfors B, Ahlmen J, Alestig K "Renal function during cefoperazone treatment." J Antimicrob Chemother 9 (1982): 485-7
  108. Konishi K, Suzuki H, Hayashi M, Saruta T "Pharmacokinetics of cefuroxime axetil in patients with normal and impaired renal function." J Antimicrob Chemother 31 (1993): 413-20
  109. Nilsson-Ehle I, Nilsson-Ehle P "Pharmacokinetics of cephalothin: accumulation of its deacetylated metabolite in uremic patients." J Infect Dis 139 (1979): 712-6
  110. "Product Information. Pfizerpen (penicillin)." Roerig Division, New York, NY.
  111. Kabins SA, Cohen S "Cephalothin serum levels in the azotemic patient." Antimicrob Agents Chemother 10 (1964): 207-14
  112. Arvidsson A, Borga O, Alvan G "Renal excretion of cephapirin and cephaloridine: evidence for saturable tubular reabsorption." Clin Pharmacol Ther 25 (1979): 870-6
  113. "Product Information. Keflin (cephalothin)." Lilly, Eli and Company, Indianapolis, IN.
  114. Leroy J, Leguy F, Borsa F, et al "Pharmacokinetics of ceftazidime in normal and uremic subjects." Antimicrob Agents Chemother 25 (1984): 638-42
  115. "Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals, Wilmington, DE.
  116. Brogard JM, Comte F, Spach MO, Lavillaureix J "Pharmacokinetics of mezlocillin in patients with kidney impairment: special reference to hemodialysis and dosage adjustments in relation to renal function." Chemotherapy 28 (1982): 318-26
  117. Walstad RA, Dahl K, Hellum KB, et al "The pharmacokinetics of ceftazidime in patients with impaired renal function and concurrent frusemide therapy." Eur J Clin Pharmacol 35 (1988): 273-9
  118. Bundtzen RW, Toothaker RD, Nielson OS, et al "Pharmacokinetics of cefuroxime in normal and impaired renal function: comparison of high-pressure liquid chromatography and microbiological assays." Antimicrob Agents Chemother 19 (1981): 443-9
  119. Hodgman T, Dasta JF, Armstrong DK, Visconti JA, Reilley TE "Ampicillin-associated seizures." South Med J 77 (1984): 1323-5
  120. Humbert G, Fillastre JP, Leroy A, Godin M, Van Winzum C "Pharmacokinetics of cefoxitin in normal subjects and in patients with renal insufficiency." Rev Infect Dis 1 (1979): 118-26
  121. Mackie K, Pavlin EG "Recurrent paralysis following piperacillin administration." Anesthesiology 72 (1990): 561-3
  122. Hillsley RE, Massey EW "Truncal asterixis associated with ceftazidime, a third-generation cephalosporin." Neurology 41 (1991): 2008
  123. Slaker RA, Danielson B "Neurotoxicity associated with ceftazidime therapy in geriatric patients with renal dysfunction." Pharmacotherapy 11 (1991): 351-2
  124. Giron JA, Meyers BR, Hirschman SZ, Srulevitch E "Pharmacokinetics of piperacillin in patients with moderate renal failure and in patients undergoing hemodialysis." Antimicrob Agents Chemother 19 (1981): 279-83
  125. Bergan T, Brodwall EK, Orjavik O "Pharmacokinetics of cefazolin in patients with normal and impaired renal function." J Antimicrob Chemother 3 (1977): 435-43
  126. Mangione A, Boudinot FD, Schultz RM, Jusko WJ "Dose-dependent pharmacokinetics of mezlocillin in relation to renal impairment." Antimicrob Agents Chemother 21 (1982): 428-35
  127. Goddard JK, Janning SW, Gass JS, Wilson RF "Cefuroxime-induced acute renal failure." Pharmacotherapy 14 (1994): 488-91
  128. Alshohaib S, Satti MS, Abunijem Z "Acute interstitial nephritis due to cefotaxime." Nephron 73 (1996): 725
  129. Czerwinski AW, Pederson JA "The pharmacology of cefamandole in patients with reduced renal function." Scand J Infect Dis 25 (1980): 45-8
  130. Pasmino P "Acute renal failure, skin rash, and eosinophilia associated with aztreonam." Am J Nephrol 8 (1988): 68-70
  131. Nielsen OS, Toothaker RD, Bundtzen RW, et al "Cefotaxime pharmacokinetics following a single intravenous dose to patients with varying renal function." Infection 8 (1980): s305-9
  132. Welling PG, Craig WA, Bundtzen RW, et al "Pharmacokinetics of piperacillin in subjects with various degrees of renal function." Antimicrob Agents Chemother 23 (1983): 881-7
  133. "Product Information. Ancef (cefazolin)." SmithKline Beecham, Philadelphia, PA.
  134. Trang JM, Monson TP, Ackerman BH, et al "Effect of age and renal function on cefonicid pharmacokinetics." Antimicrob Agents Chemother 33 (1989): 142-6
  135. Bergan T, Orjavik O, Brodwall EK "Pharmacokinetics of cefapirin in patients with normal and impaired renal functions." Arzneimittelforschung 31 (1981): 1773-6
  136. "Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn, Kalamazoo, MI.
  137. Pickering MJ, Spooner GR, Quesada A, de Cade JR "Declining renal function associated with administration of cephalothin." South Med J 63 (1970): 426-8
  138. Ehrnebo M, Nilsson SO, Boreus LO "Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man." J Pharmacokinet Biopharm 7 (1979): 429-51
  139. Wright N, Wise R, Hegarty T "Cefotetan elimination in patients with varying degrees of renal dysfunction." J Antimicrob Chemother 1 (1983): 213-6
  140. Pascual J, Liano F, Ortuno J "Cefotaxime-induced encephalopathy in an uremic patient." Nephron 54 (1990): 92
  141. Appel GB, Neu HC, Parry MF, et al "Pharmacokinetics of cefamandole in the presence of renal failure and in patients undergoing hemodialysis." Antimicrob Agents Chemother 10 (1976): 623-5
  142. Fanning WL, Gump D, Jick H "Gentamicin- and cephalothin-associated rises in blood urea nitrogen." Antimicrob Agents Chemother 10 (1976): 80-2
  143. Palla R, Panichi V, Bionda A, et al "Acute renal failure after mezlocilline." Clin Nephrol 25 (1986): 315-6
  144. Jungbluth GL, Cooper DL, Doyle GD, Chudzik GM, Jusko WJ "Pharmacokinetics of ticarcillin and clavulanic acid (timentin) in relation to renal function." Antimicrob Agents Chemother 30 (1986): 896-900
  145. "Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  146. Johnson CA, Halstenson CE, Kelloway JS, et al "Single-dose pharmacokinetics of piperacillin and tazobactam in patients with renal disease." Clin Pharmacol Ther 51 (1992): 32-41
  147. Nguyen VD, Nagelberg H, Agarwal BN "Acute interstitial nephritis associated with cefotetan therapy." Am J Kidney Dis 16 (1990): 259-61
  148. van Dalen R, Vree TB, Baars AM, Termond E "Dosage adjustment for ceftazidime in patients with impaired renal function." Eur J Clin Pharmacol 30 (1986): 597-605
  149. Bloomer HA, Barton LJ, Maddock RK "Penicillin-induced encephalopathy in uremic patients." JAMA 200 (1967): 121-3
  150. Phelps RT, Conte JE "Multiple-dose pharmacokinetics of cefonicid in patients with impaired renal function." Antimicrob Agents Chemother 29 (1986): 913-7
  151. Ohkawa M, Okasho A, Sugata T, Kuroda K "Elimination kinetics of ceftizoxime in humans with and without renal insufficiency." Antimicrob Agents Chemother 22 (1982): 308-11
  152. "Product Information. Cefizox (ceftizoxime)." Fujisawa, Deerfield, IL.
  153. Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985): s145-50
View all 153 references
Moderate

Diclox-methacillin (applies to Staphcillin) cystic fibrosis

Moderate Potential Hazard, High plausibility.

The penicillinase-resistant penicillins, dicloxacillin and methicillin, are both eliminated by the kidney. Renal elimination of these penicillins has been shown to increase in patients with cystic fibrosis, resulting in decreased peak serum drug concentrations and AUCs. Clinicians should be cognizant of these effects when prescribing or administering the antibiotics to patients with cystic fibrosis.

References

  1. Yaffe SJ, Gerbracht LM, Mosovich LL, Mattar ME, Danish M, Jusko WJ "Pharmacokinetics of methicillin in patients with cystic fibrosis." J Infect Dis 135 (1977): 828-31
  2. "Product Information. Dynapen (dicloxacillin)." Apothecon Inc, Plainsboro, NJ.
  3. "Product Information. Staphcillin (methicillin)." Apothecon Inc, Plainsboro, NJ.
Moderate

Methicillin (applies to Staphcillin) sodium/potassium

Moderate Potential Hazard, High plausibility. Applicable conditions: Congestive Heart Failure, Fluid Retention, Hypernatremia, Hypertension, Hypokalemia

Each gram of parenteral methicillin sodium contains approximately 60 to 71 mg (2.6 to 3.1 mEq) of sodium and is buffered with 50 mg of sodium citrate. The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention. In addition, hypokalemia has been reported rarely during therapy with the penicillinase-resistant penicillins, which may be particularly important to bear in mind when treating patients with low potassium reserves or fluid and electrolyte imbalance. Clinical monitoring of electrolytes is recommended if these agents are used for prolonged periods.

References

  1. "Product Information. Staphcillin (methicillin)." Apothecon Inc, Plainsboro, NJ.
  2. Andreoli SP, Kleiman MB, Glick MR, Bergstein JM "Nafcillin, pseudoproteinuria, and hypokalemic alkalosis." J Pediatr 97 (1980): 841-2
  3. Schlaeffer F "Oxacillin-associated hypokalemia." Drug Intell Clin Pharm 22 (1988): 695-6

Staphcillin (methicillin) drug interactions

There are 30 drug interactions with Staphcillin (methicillin)

Staphcillin (methicillin) alcohol/food interactions

There is 1 alcohol/food interaction with Staphcillin (methicillin)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.